Reicker Pfau represented LungLife AI (LLAI) in its admission to the AIM market of The London Stock Exchange. LungLife was admitted to AIM on July 8, 2021 and raised £17 million at a price at 176p, valuing the company at £45 million upon admission.
The Reicker Pfau team was led by partner Russell Terry.
A full article from Vox Markets can be found here.